Morrison, Randall L.

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 481

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 308

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study

Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 137

Personalized relapse prediction in patients with major depressive disorder using digital biomarkers

Vairavan, S., Rashidisabet, H., Li, Q. S., Ness, S., Morrison, R. L., Soares, C. N., Uher, R., Frey, B. N., Lam, R. W., Kennedy, S. H., et al. (2023) · Scientific Reports

Mental Health Research TopicsContext-Aware Activity Recognition Systems

Cited by 14